Deepan Selvadurai: Influence Statistics

Deepan Selvadurai

Known for:

Iop Medications | Openangle Glaucoma| Surgery Centers| Canaloplasty Trabeculotomy| Months Safety

Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile https://www.keyopinionleaders.com/Iop-Medications/Deepan-Selvadurai-3a1061aac5b92fafc7173e1bfa2033fa-wk.html

Deepan Selvadurai:Expert Impact

Concepts for whichDeepan Selvaduraihas direct influence:Iop medications,Openangle glaucoma,Surgery centers,Iop reduction,Included iop,Glaucoma oag,Canaloplasty trabeculotomy,Trabeculotomy omni.

Deepan Selvadurai:KOL impact

Concepts related to the work of other authors for whichfor which Deepan Selvadurai has influence:Omni surgical,Iop medications,Standalone trabeculotomy,Gemini study,Openangle glaucoma,Phacoemulsification patients,149 mmhg.

KOL Resume for Deepan Selvadurai

Year

Sample of concepts for which Deepan Selvadurai is among the top experts in the world.
Concept	World rank
Type to filter list:
trabeculotomy omni	#16
canaloplasty trabeculotomy	#27

Prominent publications by Deepan Selvadurai

Canaloplasty and trabeculotomy ab interno with the OMNI system combined with cataract surgery in open-angle glaucoma: 12-month outcomes from the ROMEO study.

[ PUBLICATION ]

KOL-Index: 4338

PURPOSE: To provide safety and effectiveness outcomes 12 months postsurgically for sequential canaloplasty and trabeculotomy with the OMNI system combined with cataract surgery in mild-to-moderate open-angle glaucoma (OAG).

SETTING: Eleven ophthalmology practices and surgery centers located in 8 U.S. states.

DESIGN: Retrospective, multicenter, single arm.

METHODS: Twelve surgeons contributed 81 patients meeting eligibility criteria: OAG, 12-month follow-up, and medicated intraocular ...

Known for Cataract Surgery | Iop Medications | Angle Glaucoma | Month Outcomes | Intraocular Pressure